

Nuclease-Free Genome Editing by AAVHSC Vectors Leads to *in vivo* Genome Correction and Amelioration of Disease Phenotype in a Mouse Model of Phenylketonuria (PKU)

Jason Wright, Laura Smith, Laura Adamson-Small, Seemin Ahmed, Nancy Avila, Brenda Burnham, Saswati Chatterjee, Serena Dollive, Jeff Ellsworth, Deiby Faulkner, Omar Francone, Monicah Kivaa, Dave Knowlton, Jaime Prout, Hill Rubin, Meghan Scarpitti, Danielle Sookiasian, Arnold Sengooba, Thia St.Martin, and Albert Seymour

Homology Medicines, Inc., Bedford, MA, USA

The direct correction of pathogenic variants has great potential for the treatment of genetic disorders. A novel group of Clade F adeno-associated viruses has been isolated from normal human CD34⁺ hematopoietic stem cells (AAVHSCs) and has shown high efficiency nuclease-free gene editing as well as gene transfer capabilities. Here we explore the potential of AAVHSCs for *in vivo* gene editing. AAVHSC vectors containing a promoter-less luciferase cassette flanked by sequences homologous to intron 6 of the mouse F8 gene were administered into NOD/SCID mice and resulted in liver-specific expression of luciferase for up to 9 weeks. Analysis of liver DNA display a significant proportion of successfully edited F8 with no detection of insertion or deletion mutations. To correct a disease phenotype, an AAVHSC correction vector containing a promoter-less cDNA encoding human phenylalanine hydroxylase (PAH) flanked by sequences homologous to exon 1 of the murine PAH gene was administered into a mouse model of the disease phenylketonuria (PKU). Treatment with AAVHSC vectors led to a significant correction in serum Phe levels relative to baseline. Reduction in disease phenotypes were maintained over 21 weeks post-injection and liver DNA displayed efficient gene editing and expression. In total, these data establish that the AAVHSCs are a viable platform for precise *in vivo* gene editing and correction.